Early interventions, such as erythropoietin-stimulating agents to address anaemia, bisphosphonates for calcium management, and nutritional support, may improve patient outcomes and mobility by reducing infection risk, potentially lowering VTE risk, similar to effects seen in the general population [35]. The gene discussed is EPO; the disease is anemia (phenotype).